Douglas Kerr Sells 1,290 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Douglas Kerr sold 1,290 shares of Dyne Therapeutics stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total value of $24,355.20. Following the sale, the insider owned 162,564 shares in the company, valued at $3,069,208.32. The trade was a 0.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Douglas Kerr also recently made the following trade(s):

• On Friday, September 4th, Douglas Kerr sold 3,745 shares of Dyne Therapeutics stock. The shares were sold at an average price of $24.35, for a total transaction of $91,190.75.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $19.19 on Thursday. Dyne Therapeutics, Inc. has a 52-week low of $11.92 and a 52-week high of $27.31. The company has a 50-day simple moving average of $24.77 and a 200 day simple moving average of $20.52. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. The company has a market capitalization of $3.58 billion, a PE ratio of -5.76 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, research analysts predict that Dyne Therapeutics, Inc. will post -3.47 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Handelsbanken Fonder AB purchased a new stake in shares of Dyne Therapeutics in the 2nd quarter valued at about $1,182,000. Fisher Asset Management LLC purchased a new position in shares of Dyne Therapeutics during the fourth quarter worth about $4,891,000. Royal Bank of Canada increased its position in shares of Dyne Therapeutics by 267.6% in the first quarter. Royal Bank of Canada now owns 68,188 shares of the company’s stock worth $1,236,000 after purchasing an additional 49,641 shares during the last quarter. Cibc World Market Inc. bought a new position in shares of Dyne Therapeutics in the fourth quarter worth approximately $1,345,000. Finally, Clearbridge Investments LLC purchased a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $7,976,000. Institutional investors own 96.68% of the company’s stock.

Analyst Ratings Changes

DYN has been the subject of a number of recent research reports. Sanford C. Bernstein raised their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Robert W. Baird dropped their price target on Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Friday, July 17th. Raymond James Financial reissued a “strong-buy” rating and issued a $37.00 price objective on shares of Dyne Therapeutics in a report on Tuesday. Finally, Cantor Fitzgerald began coverage on Dyne Therapeutics in a research note on Thursday, July 23rd. They issued an “overweight” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $32.17.

Key Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Royal Bank of Canada maintained an “outperform” rating, although it reduced its price target from $35 to $30. RBC said Dyne’s DYNE-101, or z-basivarsen, has important differences from Novartis’ program that could support better outcomes. RBC analysis of Dyne’s DM1 approach
• Positive Sentiment: Dyne is scheduled to present six- and 12-month ACHIEVE trial data for z-basivarsen at the World Muscle Society and AANEM meetings beginning September 29-30. The company expects topline results from its fully enrolled registrational expansion cohort in the first quarter of 2027. Dyne ACHIEVE data announcement
• Neutral Sentiment: JPMorgan downgraded DYN from “neutral” to “underweight” and cut its price target from $17 to $10, while RBC remained bullish. The sharply conflicting views highlight significant uncertainty ahead of Dyne’s clinical updates. JPMorgan downgrade report
• Neutral Sentiment: Call-option activity increased dramatically, with traders purchasing more than 20,000 calls versus an average of roughly 464. This may indicate speculative expectations for a rebound or favorable clinical data, but it does not establish a fundamental improvement.
• Negative Sentiment: Investors appear to be treating the Novartis Phase 3 failure as a warning for the DM1 drug class, causing a sharp decline in Dyne shares despite the company’s upcoming data. Report on rival DM1 trial failure
• Negative Sentiment: Several insiders, including CEO John Cox, reported stock sales. The filings state that the sales were made to cover tax withholding on vested equity awards, reducing their negative significance, but the cluster may add to cautious sentiment.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.